期刊
INFECTIOUS DISEASES AND THERAPY
卷 4, 期 -, 页码 51-64出版社
SPRINGER LONDON LTD
DOI: 10.1007/s40121-015-0080-z
关键词
Antibiotic; Antimicrobial stewardship; Healthcare-associated infections; Pharmacy; Resistance
资金
- Eumedica Pharmaceuticals
- Astellas Pharmaceuticals
- Sanofi
- Baxter
- Clinigen
- Cubist
- Eumedica
- ICNet
- Pfizer
- Merck Sharpe Dome
- Astellas Pharmaceuticals B. Braun
- Gilead
- Cubist/Merck
- UKCPA
- AstraZeneca
- Basilea/Quintiles
- Bayer
- Cubist/MSD
- Roche
- ECDC
- BSAC
Antimicrobial stewardship in the UK has evolved dramatically in the last 15 years. Factors driving this include initial central funding for specialist pharmacists and mandatory reductions in healthcare-associated infections (particularly Clostridium difficile infection). More recently, the introduction of national stewardship guidelines, and an increased focus on stewardship as part of the UK five-year antimicrobial resistance strategy, have accelerated and embedded developments. Antimicrobial pharmacists have been instrumental in effecting changes at an organizational and national level. This article describes the evolution of the antimicrobial pharmacist role, its impact, the progress toward the actions listed in the five-year resistance strategy, and novel emerging areas in stewardship in the UK.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据